Bupropion in the Treatment of Pathological Gambling
Pathological Gambling
About this trial
This is an interventional treatment trial for Pathological Gambling
Eligibility Criteria
Inclusion Criteria: Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS); Meet the criteria for Pathological Gambling (DSM-IV-TR), through the administration of the National Opinion Research Center DSM Screen for Gambling Problems(NODS); Receive a score of 5 or more on the South Oaks Gambling Screen (SOGS); Have PG for at least one year; Have had at least 2 or more gambling episodes during the 2-week screening period; Speak standard English; Be able to give written informed consent. Exclusion Criteria: Evidence of current (past 3 months) substance misuse; Had a Hamilton Depression Rating Scale (HDRS)27 score of 18 or more (or a score on item 1 of greater than 2; Had a current eating disorder (except binge eating disorder); Had any history of seizures, or suicidal or aggressive behavior; Had a urine drug screen positive for stimulants, opiates, hallucinogens, or phencyclidine; Had a current or past psychotic disorder, bipolar disorder, or significant cognitive disorder; Received monoamine oxidase inhibitors within 3 weeks of randomization, long acting phenothiazine within 3 months of randomization,fluoxetine within 4 weeks of randomization, or other psychotropic drugs within 2 weeks of randomization; Had prior exposure to bupropion; Were engaged in individual, group, or couples psychotherapy during the 2 weeks before randomization, (except Gamblers Anonymous).
Sites / Locations
- Roy J. and Lucille A. Carver College of Medicine, University of Iowa
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Subjects receivng Bupropion
Subjects receiving Placebo
The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.